NanGenex’s mission is to develop proprietary drugs, Super-APIs,  with fundamental improvements and clinically meaningful benefits over traditional drug formulations.

NanGenex’s NanoActive Super-API Technology introduces a paradigm shift in drug discovery, development and manufacturing. NanGenex’s complex and integrated intelligent approach can generate druggable active compounds in a high throughput fashion and build up a critical mass of entirely new Supra-Molecular Transformation knowledge that is unrivalled by alternative technologies.

The NanoActive HT Technology delivers new performance profiles to compounds in development or drugs in market. Without chemical modification, the technology provides resolution of dose delivery administration, bio-availability, solubility, stability and other performance limiting issues that manifest in promising new compounds in development that are “non-druggable” in their current form, and alters the effective side-effect and toxicity profiles of drugs by reducing total administered dose that is consequent upon improved drug bio-availability and pharmacokinetics.

The NanoActive Super-API Technology is a bottom-up, continuous flow based technology. Its key elements are its detection cascade, proprietary instrumentation and the novel structures of the generated Super-APIs. Super-APIs have unique structures with specific fingerprints that are characteristic to the developed compositions. These patentable structures can only be produced by the NanoActive Technology. The generated Super-APIs have dramatically enhanced apparent solubility and absorption properties giving rise to enhanced PK performance, such as improved bioavailability, decreased T_max and increased c_max.
The technology is fully integrated into the development value chain, requires mg quantities for development and scalable to aseptic GMP production.

The tecnology enables also the creation of nanostructured pharmaceutical macromolecules (e.g. polypeptides, polynucleotides).

High Throughput NanoActive Laboratory

The NanoActive Super-API Technology includes

• Parameter prediction: 

Proprietary intelligent and self-learning detection cascade system providing in silico assessment on feasibility of Super-API generation with continual improvement in excipient prediction

• HT methods:

Hit identification: Effective and rapid screening for optimal stabilizers, redispersibility profile and particle size

Analytics and optimization: Selection of compositions with best apparent solubility, enhanced ability to make the API available for absorption, which withstands the constantly changing environment while transit through the GI tract

• Compatibility screening of clinical dosage forms

• Scale-up and production of Super-APIs